Transcript Probiotics and ellen® SCIENTIFIC FACTS

Our mission
“To help women keeping a healthy intimate and vaginal balance
by providing excellent and innovative products that are easy to
use and when applicable, with a scientific background ”
Female intimate health
Restoration and
Balance
ellen®
Proven
Probiotics - Lacto Naturel
Prevention and
Protection
2013 was a lost year for Ellen
Net sales
Operating expenses
EBITDA
6%
Total assets
Number of staff
Source: Annual reports
2012
2011
17 392
23 028
18 902
-27 389
-26 018
-25 002
-2 324
-4 669
40%
40%
41%
17 684
25 333
21 048
7,5
5,5
5,5
41%
-9 553
EBITDA adjusted from
impairment of current
assets
Gross margin
2013
-6 486
31%
Milestones of the company´s development
2000
Ellen AB was founded
2001
Patent for LN® bacterial strains (valid until 2021)
2002
Patent for production process (valid until 2022)
2003
The probiotic tampon ellen® launch in Sweden
2007
ellen® launch in Austria and France
2008
Medical Device product in EU- ellen® launch in Germany
Ellen Asia Ltd was founded
2011
Ellen agreements in 37 markets & launch in 13 countries
2013
ellen® Probiotic Intimate creme was launched
A cost cutting program has been initiated and
three persons have been dismissed
 Dismissed staff are:
• Ellen has no longer a general secretary
• Research and development manager as well as brand
manager have been dismissed
 Product development is a strategic issue and resources for
development of new products became part of the sales
and marketing manager
 External resources have been added to secure the ISO
certificate instead of full time employment
The new organisation of Ellen
Share holders
Support
Board of Directors
Scientific Board
Ström & Gulliksson
Mazars SET
LA Groth
Ants
MAQS Law firm
Stefan Appelgren, Chairman
Mikael Lövgren
Ingrid Atteryd Heiman
Anders Boquist
Liao Qinping, Prof. Beijing, China
Gerd Neumann,Prof. Dr. Hamburg, Germany
Carl Påhlson,Prof Molecular biology, Sweden
Lars-Olof Berg, MSc, Microbiologist, Sweden
Dr Dvorak, MD, PhD. Czech Republic
Dr Sophia Ehrström, PhD. Sweden
CEO
Ingrid Atteryd Heiman
CFO
Production
Logistic ass.
QA/RA
Marketing & Sales
Emilie Andersson
Ylva Winberg
Charlotta Baringe
Peter Landvall
Annika Sahlin Pohl
Distributors/Partners
Suppliers
Consultants
Ellen has a distributor strategy worldwide
 Close co-operation with our partners
 Strategic marketing and sales support to our distributors
 Global brand communication – when possible
 Sharing information to encourage communication and take
advantage of good ideas and initiatives
 Product development within Female intimate health
Sales channels are mainly pharmacies and
drugstores
1. Pharmacies
2. Parapharmacies
3. Drugstores
4. Healthfood stores
5. Web-shops
Ellen prioritise to give support to our existing
partners
 Close co-operation with our partners
 Partners are divided into two groups – strategic partners and
partners with growth potentials
 Increased strategic marketing and sales support to our
partners
 Global brand communication – when possible
 Sharing information to encourage communication and take
advantage of good ideas and initiatives
 Create and support an international web-shop
Our Partners are twelve altogether
Our strategic partners are:
• IPRAD
• Ellen Vertriebs
• Navamedic
Our partners with growth potentials are:
• Transmeri, Finland
• Bio-Tech, Hungary
• Holbex, Poland
• Casen Recordati, Spain
• S&D Pharma, Czech Republic and Slovakia
• Sante HM, Romania
• Tosama, Balkan countries
• Ellen Asia
The distributors Iprad and Ellen Vertriebs
dominate the sales
Others
S&D Pharma
Czech Republic,
Slovakia
The Nordic
countries
Denmark, Finland,
Norway, Sweden,
Webshop
12%
6%
IPRAD (France, Belgium)
41%
10%
31%
Ellen Vertriebs
Germany, Austria,
Switzerland)
Sales, interim report first half of 2014
Operating expenses first half of 2014 are less
then 2013 and 2012
2014
2013
2012
Jan - June Jan - June Jan - June
Net sales
9 612
Operating expenses6%
11 964
10 415
-12 41241% -14 145
-13 300
Operating loss EBITDA
-2 480
EBITDA adjusted for
restructuring expenses
-1 418
Loss for the period
-1 806
-1 453
31% -2 400
-1 599
-1 612
43%
41%
41%
4,5
7,5
6,5
Gross margin
Number of staff
Source: Interim report first half of 2014
Our healthy body – billions of natural
lactobacilli exist in;
MAN
FEMALE
mouth
mouth
gastrointestinal tract
gastrointestinal tract
-
vaginal cavity
25% of women suffers from imbalance in their
intimate area - “100 million women in Europe”
Causes can be:
External
factors
Internal
factors
Sexual activity
Contraceptive choice
Extended hygiene, intimate
shaving
Use of antibiotics
Genetic inheritance
Hormonal changes
Age, Pregnancy,
Menstrual cycle
ellen® Probiotic Tampon - a Dual Action
Medical Device/Consumer product
Probiotics
Menstruation
protection

Restores/maintains a healthy vaginal bacterial flora

Balances the vaginal pH

Promotes vaginal health
 Comfortable, high quality menstrual protection
2 in 1 - Double action
The process and the probiotics strains
are protected by patents
Good clinical results which shows LN ® strains efficacy
and safety
- 6 clinical studies
- 3 in vitro studies
Process for production of an absorbing sanitary
article comprising lactic acid producing bacteria
- Patented until 2021-09-19 in 21 markets
Lactic acid producing bacteria for use as probiotic
organisms in the human vagina
- Patented until 2022-09-19 in 19 markets
The patented LN strains are three

Lactobacillus gasseri LN40

Lactobacillus rhamnosus LN113

Lactobacillus fermentum LN99
These strains Belong to common vaginal Lactobacillus species
They are isolated from healthy women’s vaginal flora (Lund University, Sweden)
They are genetically stable
They are the active ingredients in ellen® Probiotic tampon and intimate creme
In vitro studies of LN strains shows
LN strains produce antimicrobial substances

Produce lactic acid
+

Lower the pH
+

Produce Hydrogen Peroxide (H2O2)
+

Inhibit urogenital pathogens
Escherichia coli, Streptococcus agalactiae,
Enterococcus faecalis, Staphylococcus aureus

Inhibit yeast
Candida albicans
Adhere excellent to epithelial cells
+
+
+
LN strains – Clinically proven

Administered vaginally (tampons and capsules)
↓

Colonizes the vagina

Reduces vaginal discomfort (itching & irritation)

Reduces malodorous discharge

Improved cure rate

Reduces recurrences of BV and CV

Safe to use
Studies of ellen® products
ellen® Probiotic tampon
Clinical Study 1: 1992, Sweden (20 women)
Clinical Study 2: 2001, Sweden (16 women)
Clinical Study 3: 2006, Sweden/Norway/Finland (255 women)
Clinical Study 4: 2012, Ukraine (40 women)
__________________________________________________
LN strains (vaginal capsules)
Clinical Study 1: 2010, Sweden (95 women)
ellen® Intimate Crème
_________________________________________
Clinical Study 1: 2013, Sweden (95 women) Under publication
Consumer study 1: 2012, Sweden (29 women)
Consumer study 2: 2013, Sweden (92 women)
______________________________________________
Ellen Probiotic tampon is the only one
in the world
 Tampon with natural lactobacilli
 Three different sizes
 With or without applicators
Recommendations

Minimum 3 tampons per day during 3 days in a period

Choose the right size according to bleeding

All women who are menstruating

Women who are in danger of getting recurrant vaginal
infections

All women who just used antibiotics of any kind

When swimming and frequent washing
Add-on product – for campaigns or regular
Available
now!
Monthly Pack!
Probiotic tampons + regular tampons
Normal size 12 + 12
All tampons you need in one
menstruation!
Test sales in Germany
ellen® Probiotic Intimate Crème
For a dry and sensitive external intimate area
 2 in 1 – Natural lactobacilli and Natural fats/oils
 No preservatives
 No perfume
 No water
Double action cosmetic product
 Moisturize


Softens the external mucus membranes

Prevent dryness

Give a natural and fresh feeling
Helps to maintain a natural microbial flora

Contribute to the body’s natural bacterial flora and barrier
(hydrolipidic film) in the external intimate area
Natural
ingredients
Target group

Dryness in the intimate area

Have a sense of not being fresh

Bad odour

Protection against unwanted bacteria

Fertile women

Menopausal and postmenopausal women
Proffessional feedback
Gynecologists comments:

Unique - without water, perfume and preservatives

Lactobacilli - no other crème on the market containing probiotic
bacteria, specific for the vaginal area

Protection - very important to protect all 3 entrances (Urinary tract,
Vagina and Anal opening) from bad bacteria

Relief - almost immediate effect when it comes to symptoms
Summary – Why ellen® Probiotic Intimate creme?
 Can be used by all women – fertile, active, young, menopausal,
pregnant etc.
 Protective Barrier against unwanted bacteria
 Unique with proven probiotics, LN complex
 Swedish Quality, invention and production
 Tested and proven
 Natural and free from preservatives, perfume, estrogen and water
 Can be used in combination with antibiotics and antimycotics
 Complement to the probiotic tampons
New products resently developed is an intimate
wash foam

Salvia Officinalis (Sage oil)




Anti-inflammatory
Prevents from bad odour
Eco cert approved
Lactic Acid
 pH-balanced (6)

Foam
 Less water – do not dry out the skin
 Lasts longer
 Gentle against the mucosa
Good combination with the Intimate creme
Natural & Eco-Friendly
Dermatologically tested
Why Intimate deo?

Salvia Officinalis (Sage oil)



Anti-inflammatory
Anti odour – prevents sweat formation
Eco cert approved
 Lactic Acid
 pH-balanced (5)
 Deo




24 hour effect
Refreshing & Gentle
Free from Aluminium
Quick absorption
Good combination with the Intimate creme
Natural & Eco-Friendly
Dermatologically tested
Thank you!
Ingrid Atteryd Heiman
tfVD, Ellen AB
Emilie Andersson
CFO, Ellen AB